Targeting Enzymes in the Brain series, highlights new advances in the field, with this new volume presenting interesting chapters. Each chapter is written by an international board of authors.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Contributors - p. iv 7. Preface - p. xiv 8. Chapter One: Targeting PAAN/MIF nuclease activity in parthanatos-associated brain diseases - p. 1 9. Chapter Two: Inhibition of brain glutamate carboxypeptidase II (GCPII) to enhance cognitive function - p. 27 10. Chapter Three: Neutral sphingomyelinase 2: A promising drug target for CNS disease - p. 65 11. Chapter Four: Biological and therapeutic significance of targeting NLRP3 inflammasome in the brain and the current efforts to develop brain-penetrant inhibitors - p. 103 12. Chapter Five: Phosphodiesterase 4 (PDE4) and neurological disorders: A promising frontier in neuropharmacology - p. 159 13. Chapter Six: Modulatory and protective effects of prolyl hydroxylase domain inhibitors in the central nervous system - p. 211 14. Chapter Seven: Soluble epoxide hydrolase: Mechanisms and therapeutic potential in psychiatric and neurological disorders - p. 237 15. Chapter Eight: Drug discovery strategy for TAK-418, a specific inhibitor of LSD1 enzyme activity, as a novel therapy for autism - p. 267 16. Chapter Nine: Evolution of D-amino acid oxidase inhibitors: From concept to clinic - p. 301
Targeting Enzymes in the Brain series, highlights new advances in the field, with this new volume presenting interesting chapters. Each chapter is written by an international board of authors.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Contributors - p. iv 7. Preface - p. xiv 8. Chapter One: Targeting PAAN/MIF nuclease activity in parthanatos-associated brain diseases - p. 1 9. Chapter Two: Inhibition of brain glutamate carboxypeptidase II (GCPII) to enhance cognitive function - p. 27 10. Chapter Three: Neutral sphingomyelinase 2: A promising drug target for CNS disease - p. 65 11. Chapter Four: Biological and therapeutic significance of targeting NLRP3 inflammasome in the brain and the current efforts to develop brain-penetrant inhibitors - p. 103 12. Chapter Five: Phosphodiesterase 4 (PDE4) and neurological disorders: A promising frontier in neuropharmacology - p. 159 13. Chapter Six: Modulatory and protective effects of prolyl hydroxylase domain inhibitors in the central nervous system - p. 211 14. Chapter Seven: Soluble epoxide hydrolase: Mechanisms and therapeutic potential in psychiatric and neurological disorders - p. 237 15. Chapter Eight: Drug discovery strategy for TAK-418, a specific inhibitor of LSD1 enzyme activity, as a novel therapy for autism - p. 267 16. Chapter Nine: Evolution of D-amino acid oxidase inhibitors: From concept to clinic - p. 301
